why choose us

First received: December 10, 2024

Clinical Trial: Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Mild Cognitive Impairment

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment.

Brief Summary: This Phase I/II clinical trial aims to test the effectiveness of a new sublingual formulation of 5-MeO-DMT in reducing symptoms of anxiety, depression, and cognitive decline in individuals with mild to moderate Alzheimer's disease.The study will include participants who have a Clinical Dementia Rating (CDR) score between 0.5 and 1, indicating mild to moderate cognitive impairment, and who meet specific educational and cognitive criteria.Participants must have an ACE-III score of ?86 for individuals with…

Read more